Targeting angiogenesis in head and neck cancer

Maria Vassilakopoulou; Amanda Psyrri; Athanassios Argiris

doi:10.1016/j.oraloncology.2015.01.006

Targeting angiogenesis in head and neck cancer

Maria Vassilakopoulou, Amanda Psyrri, Athanassios Argiris

Medicine

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

Angiogenesis is a crucial step in tumor growth and metastasis. Head and neck squamous cell carcinomas (HNSCC) highly express angiogenesis factors, such as vascular endothelial growth factor (VEGF), which are associated with patient prognosis. Antiangiogenesis agents can potentially modulate tumor microenvironment and induce radiosensitivity and chemosensitivity. In this review, we discuss the molecular mechanisms underlying angiogenesis involved in HNSCC, preclinical data with antiangiogenesis agents as well as potential predictive biomarkers. We also review novel therapies under investigation and summarize the results of clinical trials using antiangiogenesis agents alone or in combination with conventional therapies in HNSCC.

Original language	English (US)
Pages (from-to)	409-415
Number of pages	7
Journal	Oral Oncology
Volume	51
Issue number	5
DOIs	https://doi.org/10.1016/j.oraloncology.2015.01.006
State	Published - 2015

Keywords

Angiogenesis
Bevacizumab
Head and neck cancer
Monoclonal antibodies
Targeted therapy
Tyrosine kinase inhibitors
Vascular endothelial growth factor
Vascular endothelial growth factor receptor

ASJC Scopus subject areas

Oncology
Oral Surgery
Cancer Research

Access to Document

10.1016/j.oraloncology.2015.01.006

Cite this

@article{37f49f87679f41de8a06b968d42a3988,

title = "Targeting angiogenesis in head and neck cancer",

abstract = "Angiogenesis is a crucial step in tumor growth and metastasis. Head and neck squamous cell carcinomas (HNSCC) highly express angiogenesis factors, such as vascular endothelial growth factor (VEGF), which are associated with patient prognosis. Antiangiogenesis agents can potentially modulate tumor microenvironment and induce radiosensitivity and chemosensitivity. In this review, we discuss the molecular mechanisms underlying angiogenesis involved in HNSCC, preclinical data with antiangiogenesis agents as well as potential predictive biomarkers. We also review novel therapies under investigation and summarize the results of clinical trials using antiangiogenesis agents alone or in combination with conventional therapies in HNSCC.",

keywords = "Angiogenesis, Bevacizumab, Head and neck cancer, Monoclonal antibodies, Targeted therapy, Tyrosine kinase inhibitors, Vascular endothelial growth factor, Vascular endothelial growth factor receptor",

author = "Maria Vassilakopoulou and Amanda Psyrri and Athanassios Argiris",

year = "2015",

doi = "10.1016/j.oraloncology.2015.01.006",

language = "English (US)",

volume = "51",

pages = "409--415",

journal = "Oral Oncology",

issn = "1368-8375",

publisher = "Elsevier Limited",

number = "5",

}

TY - JOUR

T1 - Targeting angiogenesis in head and neck cancer

AU - Vassilakopoulou, Maria

AU - Psyrri, Amanda

AU - Argiris, Athanassios

PY - 2015

Y1 - 2015

N2 - Angiogenesis is a crucial step in tumor growth and metastasis. Head and neck squamous cell carcinomas (HNSCC) highly express angiogenesis factors, such as vascular endothelial growth factor (VEGF), which are associated with patient prognosis. Antiangiogenesis agents can potentially modulate tumor microenvironment and induce radiosensitivity and chemosensitivity. In this review, we discuss the molecular mechanisms underlying angiogenesis involved in HNSCC, preclinical data with antiangiogenesis agents as well as potential predictive biomarkers. We also review novel therapies under investigation and summarize the results of clinical trials using antiangiogenesis agents alone or in combination with conventional therapies in HNSCC.

AB - Angiogenesis is a crucial step in tumor growth and metastasis. Head and neck squamous cell carcinomas (HNSCC) highly express angiogenesis factors, such as vascular endothelial growth factor (VEGF), which are associated with patient prognosis. Antiangiogenesis agents can potentially modulate tumor microenvironment and induce radiosensitivity and chemosensitivity. In this review, we discuss the molecular mechanisms underlying angiogenesis involved in HNSCC, preclinical data with antiangiogenesis agents as well as potential predictive biomarkers. We also review novel therapies under investigation and summarize the results of clinical trials using antiangiogenesis agents alone or in combination with conventional therapies in HNSCC.

KW - Angiogenesis

KW - Bevacizumab

KW - Head and neck cancer

KW - Monoclonal antibodies

KW - Targeted therapy

KW - Tyrosine kinase inhibitors

KW - Vascular endothelial growth factor

KW - Vascular endothelial growth factor receptor

UR - http://www.scopus.com/inward/record.url?scp=84933674222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933674222&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2015.01.006

DO - 10.1016/j.oraloncology.2015.01.006

M3 - Article

C2 - 25680863

AN - SCOPUS:84933674222

VL - 51

SP - 409

EP - 415

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

IS - 5

ER -

Targeting angiogenesis in head and neck cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this